NHS England to Offer Veoza as Non-Hormonal Treatment for Hot Flushes

In Brief

Veoza, a non-hormonal drug for hot flushes, will be available on the NHS for eligible women.

Key Facts

• Veoza, also known as fezolinetant, will be available on the NHS in England.
• The drug is intended for women for whom hormone replacement therapy (HRT) is unsuitable.
• More than 500,000 women in England could benefit from this treatment.
• The National Institute for Health and Care Excellence has authorised Veoza for NHS use.
• Veoza is a non-hormonal daily pill designed to prevent hot flushes.

What Happened

The NHS in England will offer Veoza, a non-hormonal medication, to women experiencing hot flushes who cannot use HRT, following approval from the National Institute for Health and Care Excellence.

Why It Matters

This decision provides a new treatment option for women who cannot use HRT, addressing a significant unmet need for managing menopausal symptoms such as hot flushes.

What's Next

Eligible women are expected to gain access to Veoza through the NHS. Further monitoring and assessment of the drug's impact and uptake may follow.